NKGen Biotech (NYSE:NKGN – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 20.0% of NKGen Biotech shares are held by insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares NKGen Biotech and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NKGen Biotech | N/A | N/A | -243.41% |
| Monte Rosa Therapeutics | N/A | -70.40% | -44.71% |
Volatility & Risk
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for NKGen Biotech and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NKGen Biotech | 0 | 0 | 0 | 0 | N/A |
| Monte Rosa Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Monte Rosa Therapeutics has a consensus target price of $13.75, suggesting a potential upside of 130.70%. Given Monte Rosa Therapeutics’ higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than NKGen Biotech.
Valuation & Earnings
This table compares NKGen Biotech and Monte Rosa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NKGen Biotech | $80,000.00 | 280.45 | -$82.94 million | N/A | N/A |
| Monte Rosa Therapeutics | $5.76 million | 52.27 | -$135.35 million | ($2.52) | -2.37 |
NKGen Biotech has higher earnings, but lower revenue than Monte Rosa Therapeutics.
Summary
Monte Rosa Therapeutics beats NKGen Biotech on 6 of the 10 factors compared between the two stocks.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for NKGen Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NKGen Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
